Abstract Background Cell cycle dysregulation is common in human malignancies. and CDK4/6 inhibitors targeting cell cycle have potential antitumor activity. SHR6390 is a novel small molecule inhibitor specifically targeting the CDK4/6 pathway. However. https://www.hindigyanvishv.com/save-now-Mars-Landing-Kale-Seeds-limited-super/